Hydrogen sulfide and cancer

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Recent studies revealed increased expression of various hydrogen sulfide (H<inf>2</inf>S)- producing enzymes in cancer cells of various tissue types, and new roles of H<inf>2</inf>S in the pathophysiology of cancer have emerged. This is particularly evident in cancers of the colon and ovaries, where the malignant cells both overexpress cystathionine-β-synthase (CBS) and produce increased amounts of H<inf>2</inf>S, which enhances tumor growth and spread by (a) stimulating cellular bioenergetics, (b) activating proliferative, migratory, and invasive signaling pathways, and (c) enhancing tumor angiogenesis. Importantly, in preclinical models of these cancers, either pharmacological inhibition or genetic silencing of CBS was shown to be sufficient to suppress cancer cell bioenergetics in vitro, inhibit tumor growth and metastasis in vivo, and enhance the antitumor efficacy of frontline chemotherapeutic agents, providing a strong rationale for the development of CBS-targeted inhibitors as anticancer therapies. However, the observation that inhibition of H<inf>2</inf>S biosynthesis exerts anticancer effects is contradicted by other studies showing that increasing H<inf>2</inf>S with exogenous donors also exerts antitumor actions. Herein, we present a brief review of the scientific literature documenting the function of H<inf>2</inf>S, H<inf>2</inf>S donors, and transsulfuration enzymes in cancers from various tissue types, and propose that the paradoxical actions of H<inf>2</inf>S can be resolved by considering the bell-shaped pharmacology of H<inf>2</inf>S, whereby lower (endogenous) H<inf>2</inf>S production tends to promote, while higher (generated from exogenously added H<inf>2</inf>S donors) tends to inhibit cancer cell proliferation. Finally, we suggest areas for future investigations to expand our knowledge of this nascent field.

Original languageEnglish (US)
Pages (from-to)233-241
Number of pages9
JournalHandbook of Experimental Pharmacology
Volume230
DOIs
StatePublished - 2015

Fingerprint

Hydrogen Sulfide
Tumors
Cells
Cystathionine
Tissue
Neoplasms
Biosynthesis
Cell proliferation
Enzymes
Energy Metabolism
Pharmacology
Growth
Ovarian Neoplasms
Colonic Neoplasms
Cell Proliferation
Neoplasm Metastasis

Keywords

  • Angiogenesis
  • Bioenergetics
  • Cancer
  • Hydrogen sulphide
  • Mitochondria
  • Proliferation
  • Signaling

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

Hydrogen sulfide and cancer. / Hellmich, Mark; Szabo, Csaba.

In: Handbook of Experimental Pharmacology, Vol. 230, 2015, p. 233-241.

Research output: Contribution to journalArticle

@article{fba1ab81642f47e0930e7933216d43a0,
title = "Hydrogen sulfide and cancer",
abstract = "Recent studies revealed increased expression of various hydrogen sulfide (H2S)- producing enzymes in cancer cells of various tissue types, and new roles of H2S in the pathophysiology of cancer have emerged. This is particularly evident in cancers of the colon and ovaries, where the malignant cells both overexpress cystathionine-β-synthase (CBS) and produce increased amounts of H2S, which enhances tumor growth and spread by (a) stimulating cellular bioenergetics, (b) activating proliferative, migratory, and invasive signaling pathways, and (c) enhancing tumor angiogenesis. Importantly, in preclinical models of these cancers, either pharmacological inhibition or genetic silencing of CBS was shown to be sufficient to suppress cancer cell bioenergetics in vitro, inhibit tumor growth and metastasis in vivo, and enhance the antitumor efficacy of frontline chemotherapeutic agents, providing a strong rationale for the development of CBS-targeted inhibitors as anticancer therapies. However, the observation that inhibition of H2S biosynthesis exerts anticancer effects is contradicted by other studies showing that increasing H2S with exogenous donors also exerts antitumor actions. Herein, we present a brief review of the scientific literature documenting the function of H2S, H2S donors, and transsulfuration enzymes in cancers from various tissue types, and propose that the paradoxical actions of H2S can be resolved by considering the bell-shaped pharmacology of H2S, whereby lower (endogenous) H2S production tends to promote, while higher (generated from exogenously added H2S donors) tends to inhibit cancer cell proliferation. Finally, we suggest areas for future investigations to expand our knowledge of this nascent field.",
keywords = "Angiogenesis, Bioenergetics, Cancer, Hydrogen sulphide, Mitochondria, Proliferation, Signaling",
author = "Mark Hellmich and Csaba Szabo",
year = "2015",
doi = "10.1007/978-3-319-18144-8_12",
language = "English (US)",
volume = "230",
pages = "233--241",
journal = "Handbook of Experimental Pharmacology",
issn = "0171-2004",
publisher = "Springer Heidelberg",

}

TY - JOUR

T1 - Hydrogen sulfide and cancer

AU - Hellmich, Mark

AU - Szabo, Csaba

PY - 2015

Y1 - 2015

N2 - Recent studies revealed increased expression of various hydrogen sulfide (H2S)- producing enzymes in cancer cells of various tissue types, and new roles of H2S in the pathophysiology of cancer have emerged. This is particularly evident in cancers of the colon and ovaries, where the malignant cells both overexpress cystathionine-β-synthase (CBS) and produce increased amounts of H2S, which enhances tumor growth and spread by (a) stimulating cellular bioenergetics, (b) activating proliferative, migratory, and invasive signaling pathways, and (c) enhancing tumor angiogenesis. Importantly, in preclinical models of these cancers, either pharmacological inhibition or genetic silencing of CBS was shown to be sufficient to suppress cancer cell bioenergetics in vitro, inhibit tumor growth and metastasis in vivo, and enhance the antitumor efficacy of frontline chemotherapeutic agents, providing a strong rationale for the development of CBS-targeted inhibitors as anticancer therapies. However, the observation that inhibition of H2S biosynthesis exerts anticancer effects is contradicted by other studies showing that increasing H2S with exogenous donors also exerts antitumor actions. Herein, we present a brief review of the scientific literature documenting the function of H2S, H2S donors, and transsulfuration enzymes in cancers from various tissue types, and propose that the paradoxical actions of H2S can be resolved by considering the bell-shaped pharmacology of H2S, whereby lower (endogenous) H2S production tends to promote, while higher (generated from exogenously added H2S donors) tends to inhibit cancer cell proliferation. Finally, we suggest areas for future investigations to expand our knowledge of this nascent field.

AB - Recent studies revealed increased expression of various hydrogen sulfide (H2S)- producing enzymes in cancer cells of various tissue types, and new roles of H2S in the pathophysiology of cancer have emerged. This is particularly evident in cancers of the colon and ovaries, where the malignant cells both overexpress cystathionine-β-synthase (CBS) and produce increased amounts of H2S, which enhances tumor growth and spread by (a) stimulating cellular bioenergetics, (b) activating proliferative, migratory, and invasive signaling pathways, and (c) enhancing tumor angiogenesis. Importantly, in preclinical models of these cancers, either pharmacological inhibition or genetic silencing of CBS was shown to be sufficient to suppress cancer cell bioenergetics in vitro, inhibit tumor growth and metastasis in vivo, and enhance the antitumor efficacy of frontline chemotherapeutic agents, providing a strong rationale for the development of CBS-targeted inhibitors as anticancer therapies. However, the observation that inhibition of H2S biosynthesis exerts anticancer effects is contradicted by other studies showing that increasing H2S with exogenous donors also exerts antitumor actions. Herein, we present a brief review of the scientific literature documenting the function of H2S, H2S donors, and transsulfuration enzymes in cancers from various tissue types, and propose that the paradoxical actions of H2S can be resolved by considering the bell-shaped pharmacology of H2S, whereby lower (endogenous) H2S production tends to promote, while higher (generated from exogenously added H2S donors) tends to inhibit cancer cell proliferation. Finally, we suggest areas for future investigations to expand our knowledge of this nascent field.

KW - Angiogenesis

KW - Bioenergetics

KW - Cancer

KW - Hydrogen sulphide

KW - Mitochondria

KW - Proliferation

KW - Signaling

UR - http://www.scopus.com/inward/record.url?scp=84936996072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936996072&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-18144-8_12

DO - 10.1007/978-3-319-18144-8_12

M3 - Article

VL - 230

SP - 233

EP - 241

JO - Handbook of Experimental Pharmacology

JF - Handbook of Experimental Pharmacology

SN - 0171-2004

ER -